GPI-15715 Guilford

Curr Opin Investig Drugs. 2005 Jan;6(1):90-8.

Abstract

GPI-15715 (PQ-1002, Aquavan), a water-soluble prodrug of propofol, is being developed by Guilford, under license from ProQuest, as a potential anesthetic agent. In May 2004, Guilford initiated phase III trials in the US to evaluate the sedative effects of this prodrug in several patient populations.

Publication types

  • Review

MeSH terms

  • Anesthetics, Intravenous* / adverse effects
  • Anesthetics, Intravenous* / pharmacology
  • Anesthetics, Intravenous* / therapeutic use
  • Animals
  • Clinical Trials as Topic
  • Humans
  • Prodrugs* / adverse effects
  • Prodrugs* / pharmacology
  • Prodrugs* / therapeutic use
  • Propofol* / adverse effects
  • Propofol* / analogs & derivatives*
  • Propofol* / pharmacology
  • Propofol* / therapeutic use

Substances

  • Anesthetics, Intravenous
  • Prodrugs
  • fospropofol
  • Propofol